In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Idorsia has extended its cash runway into 2025 via an exclusivity fee for global rights negotiations for Tryvio.

The EC has granted approval to Novartis' Kisqali (ribociclib) plus an aromatase inhibitor to treat early breast cancer ...

Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive ...

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

In an advancement for diabetes management, the US Food and Drug Administration (FDA) has granted clearance to Medtronic’s new ...

Discover the leading lead generation providers and technology solutions tailored for the pharmaceutical industry. Download our guide for industry insights and technology solution information.

Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711.

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.